Revenue $3.46B, up 6.7% on a year earlier. Diluted EPS $0.82 against $0.70.
| Q2 FY26 | Q1 FY26 | Q2 FY25 | Year over year | |
|---|---|---|---|---|
| Revenue | $3.46B | $3.37B | $3.24B | +6.7% |
| Operating income | $171.00M | $182.00M | $151.00M | +13.2% |
| Net income | $94.00M | $107.00M | $86.00M | +9.3% |
| Diluted EPS | $0.82 | $0.92 | $0.70 | |
| Operating cash flow | $242.00M | -$97.00M | $120.00M | +101.7% |
| Capital expenditures | -$30.00M | -$25.00M | -$32.00M | |
| Free cash flow | $212.00M | -$122.00M | $88.00M | +140.9% |
| Q2 FY26 | Q2 FY25 | Year over year | |
|---|---|---|---|
| Foreign exchange impact on sales | 1.4% | 0.6% | |
| Internal sales growth | 4.6% | 1.9% | |
| Local currency net sales growth | 4.6% | 1.9% | |
| Medical sales | $1.06B | $1.02B | +4.0% |
| Net sales growth | 6.7% | 3.32% |
The week's biggest guidance misses, KPI surprises and one chart.
Stock Atlas, “Henry Schein (HSIC) Q2 FY26 earnings: results and KPIs”, stockatlas.com/companies/HSIC/earnings/2026-q2/, data as of 3 November 2026. Links to this page are welcome.
